Corbus Pharmaceuticals 株価情報 (NASDAQ: CRBP)

最新ニュース Corbus Pharmaceuticals (NASDAQ:CRBP) 株価情報

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals Holdings Inc

Raymond James analyst Michael Rose reiterates Red River Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRBI#NASDAQ">RRBI</a>) with a Outperform and raises the price target from $57 to $62.

News

Price Target

Reiteration

Analyst Ratings

RRBI

Raymond James Reiterates Outperform on Red River Bancshares, Raises Price Target to $62

Raymond James analyst Brian Peterson reiterates Paylocity Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCTY#NASDAQ">PCTY</a>) with a Outperform and lowers the price target from $265 to $235.

PCTY

Raymond James Reiterates Outperform on Paylocity Holding, Lowers Price Target to $235

Guggenheim analyst Shahriar Pourreza reiterates Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>) with a Neutral and maintains $93 price target.

Guggenheim Reiterates Neutral on Southern, Maintains $93 Price Target

Raymond James analyst Joseph Altobello maintains Patrick Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PATK#NASDAQ">PATK</a>) with a Outperform and lowers the price target from $103 to $95.

PATK

Raymond James Maintains Outperform on Patrick Industries, Lowers Price Target to $95

Palantir Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares climbed 5.4% to $122.52 during Friday&#8217;s session, near their all-time high and up over 400% over the past year, as investor enthusiasm builds ahead of its Monday earnings report. The rally follows a string of <a href="https://www.benzinga.com/trading-ideas/movers/25/04/45113101/palantir-stock-is-up-55-ytd-heading-into-earnings-next-week-whats-going-on">high-profile defense deals</a> and ongoing momentum from its fourth-quarter performance.
What To Know: Palantir recently delivered two battlefield TITAN systems to the U.S. Army and announced a new partnership with NATO Allied Command Operations to provide AI-powered military technology. Its Maven Smart System aims to enhance battlefield decision-making through advanced AI.
Read Also: <a href="https://www.benzinga.com/news/25/05/45168991/starbucks-sbux-stock-plunges-10-this-week-on-earnings-miss-recovers-losses">Starbucks Stock Plunges 10% This Week On Earnings Miss, Recovers Losses</a>
Analysts are meanwhile <a href="https://www.benzinga.com/trading-ideas/movers/25/04/45113101/palantir-stock-is-up-55-ytd-heading-into-earnings-next-week-whats-going-on">divided</a> on the stock; Wedbush's Dan Ives remains bullish, calling the NATO deal a "major win," while RBC Capital maintains an Underperform rating. 
In the fourth-quarter, Palantir posted <a href="https://www.benzinga.com/news/earnings/25/02/43449486/palantir-q4-earnings-revenue-beat-eps-beat-us-revenue-up-52-customer-count-up-43-strong-guidance-this-is-a-new-phase-unlike-anything-that-has-come-before">$827.52 million in revenue</a> and 14 cents in adjusted EPS, beating estimates and growing U.S. revenue by 52% year-over-year. The company closed 129 deals over $1 million and ended the quarter with $5.2 billion in cash. 
For the first-quarter, Palantir expects up to $862 million in revenue and sees full-year 2025 revenue hitting up to $3.76 billion. With the stock up over 444% over the past year, investors are watching closely to see if the upward trend continues.
Read Also: <a href="https://www.benzinga.com/news/25/05/45169536/qualcomm-qcom-stock-falls-6-this-week-despite-q2-earnings-beat">Qualcomm Stock Falls 6% This Week Despite Q2 Earnings Beat</a>
<h2 class="wp-block-heading">How To Buy PLTR Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Palantir Technologies&#8217; case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, PLTR has a 52-week high of $125.41 and a 52-week low of $20.50.

PLTR

Palantir (PLTR) Stock Is Up Over 400% Ahead of Monday's Earnings Report: What's Going On?

Raymond James analyst Melissa Fairbanks reiterates Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) with a Outperform and lowers the price target from $925 to $720.

MPWR

Raymond James Reiterates Outperform on Monolithic Power Systems, Lowers Price Target to $720

Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) has outperformed the market over the past 10 years by 1.85% on an annualized basis producing an average annual return of 12.37%. Currently, Analog Devices has a market capitalization of $98.80 billion. 
Buying $100 In ADI: If an investor had bought $100 of ADI stock 10 years ago, it would be worth $323.16 today based on a price of $199.19 for ADI at the time of writing.
<h3>Analog Devices's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746203414_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Analog Devices Stock In The Last 10 Years

CACI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>) has outperformed the market over the past 15 years by 5.13% on an annualized basis producing an average annual return of 16.29%. Currently, CACI International has a market capitalization of $10.32 billion. 
Buying $1000 In CACI: If an investor had bought $1000 of CACI stock 15 years ago, it would be worth $9,789.02 today based on a price of $469.19 for CACI at the time of writing.
<h3>CACI International's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746203414_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CACI

$1000 Invested In CACI International 15 Years Ago Would Be Worth This Much Today

Raymond James analyst Andrew Cooper reiterates Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Outperform and lowers the price target from $90 to $71.

HOLX

Raymond James Reiterates Outperform on Hologic, Lowers Price Target to $71

Guggenheim analyst Michael Morris reiterates Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Buy and maintains $100 price target.

ROKU

Guggenheim Reiterates Buy on Roku, Maintains $100 Price Target

WIIM

Becton, Dickinson and Company shares are trading lower after Stifel maintained a Buy rating on the stock and lowered its price target from $280 to $224. Also, Piper Sandler downgraded the stock from Overweight to Neutral and lowered its price target from $260 to $185.

Raymond James analyst Matt Roberts reiterates Graphic Packaging Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPK#NYSE">GPK</a>) with a Outperform and lowers the price target from $30 to $26.

Raymond James Reiterates Outperform on Graphic Packaging Holding, Lowers Price Target to $26

Raymond James analyst Patrick Tyler Brown reiterates GFL Environmental (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>) with a Outperform and raises the price target from $56 to $57.

Raymond James Reiterates Outperform on GFL Environmental, Raises Price Target to $57

Raymond James analyst Daniel Tamayo reiterates First Mid Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FMBH#NASDAQ">FMBH</a>) with a Outperform and lowers the price target from $43 to $40.

FMBH

Raymond James Reiterates Outperform on First Mid Bancshares, Lowers Price Target to $40

Shares of Roku Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) fell in early trading on Friday despite the company&#8217;s upbeat <a href="https://www.benzinga.com/news/earnings/25/05/45152693/roku-q1-double-beat-adds-new-streaming-platform-shares-drop-on-cautious-guidance-tariff-risks">first-quarter results on Thursday.</a>
The announcement came amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
Rosenblatt Securities On Roku
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586cf168351b9b0001a3054e/barton-crockett">Analyst Barton Crockett</a> reiterated a Neutral rating, while slashing the price target from $100 to $75.
Although Roku&#8217;s first-quarter results were positive, with 16% year-on-year revenue growth and 37% growth in adjusted EBITDA, they were near expectations, Crockett said in a note. The company expected revenue growth to decelerate to 11% in the second quarter, with a decline in the Devices business line, he added.
Management projected second-quarter adjusted EBITDA of $70 million, the analyst stated. While the deceleration in Devices "shouldn&#8217;t matter," the stock could continue trading at a lower multiple "in this environment," he further wrote.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Needham On Roku
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/580607ae846faa000106ab43/laura-martin">Analyst Laura Martin</a> maintained a Buy rating and price target of $88.50.
Roku reported strong quarterly results, with revenues of $1.02 billion and adjusted EBITDA of $56 million, above expectations, Martin said. The company reiterated its full-year Platform segment revenue guidance of $3.95 billion, up 12% year-on-year, she added.
While Roku&#8217;s underlying growth is likely to be mid-teens in 2025, revenue growth may decelerate slightly in the back half of the year due to tough comps, the analyst stated. "Roku is our top pick for 2025," he further wrote.
JPMorgan On Roku
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/6006d04ba6fe6f00019855f6/cory-carpenter">Analyst Cory Carpenter</a> reaffirmed an Overweight rating and price target of $75.
Roku's Platform revenues grew 17% in the first quarter, slightly exceeded the guidance of 16%, Carpenter said. Management reiterated full-year Platform growth of 12%, he added.
"We believe Roku is likely to be more resilient than before given its programmatic integrations, a more diversified Platform revenue base that relies less on M&amp;E &amp; direct scatter buys, and a mgmt team more focused on monetization," the analyst wrote.
Guggenheim Securities On Roku
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58b59ca9b85e930001267b7f/michael-morris">Analyst Michael Morris</a> reiterated a Buy rating and price target of $100.
Roku reported broadly in-line quarterly results and projected Platform revenue growth of 14% for the second quarter, higher than consensus of 13%, Morris said. The full-year guidance reflects contribution from the Frndly TV acquisition, he added.
The company expects to close the acquisition towards the end of the second quarter and for it to be adjusted EBITDA margin accretive in the first full year, the analyst stated. "Anticipate slight step down in 4Q Platform revenue growth due to tough comp (+19% in 4Q24)," he further wrote.
Benchmark On Roku
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d3cdb7b85e930001808a59/daniel-kurnos">Analyst Daniel Kurnos</a> reaffirmed a Buy rating and price target of $130.
Roku essentially kept its full-year guidance unchanged, "despite some overall pricing softness," Kurnos said. The pricing issues were more than offset by volume growth, he added.
Although the full-year guidance reflects contributions from an acquisition, the company is small and the deal will not even close until late in the second quarter, the analyst stated. "Yes, it is true that 1Q lacked the standard upside we have all come to expect on a current quarter, but the 2Q outlook was solid on platform across the board after factoring in a touch more gross margin sensitivity as mix shifts incrementally towards programmatic," he further wrote.
Wedbush On Roku
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/61a5f4316788ac00012ad71d/alicia-reese">Analyst Alicia Reese</a> maintained an Outperform rating and price target of $100.
Roku reported revenues of $1.021 billion, beating consensus of $1.007 billion, Reese said. "Roku maintained its 2025 EBITDA guidance and 2026 target for positive operating income, emphasizing its focus on profitable expansion," she added.
Roku is expanding its ARPU (average revenue per user) through increased ad inventory and enhanced targeting, the analyst stated.
Citizens On Roku
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/668279aa7ee1530001b49265/matthew-condon">Analyst Matthew Condon</a> reaffirmed a Market Outperform rating and price target of $95.
Our key takeaway is that Roku is not seeing any material impact on advertising demand from the "macro environment in 2Q, as it reiterated its 2025 platform revenue and EBITDA guidance," Condon said. Advertisers are shifting their spend to "non-guaranteed programmatic buying for increased flexibility and measurable ROI amid macro uncertainty" and Roku is well positioned to meet the increase in demand, he added.
"While this shift impacts platform gross profit margins in the near term, we believe Roku is tapping into incremental demand with its programmatic capabilities, which should benefit the company long term," the analyst further wrote.
ROKU Price Action: Shares of Roku had declined by 6.7% to $62.70 at the time of publication on Friday.
Read More:
<ul>
<li> <a href="https://www.benzinga.com/news/25/04/45045012/sabre-divests-hospitality-arm-tpg-plans-debt-reductioncore-platform-focus"> Warren Buffett&#8217;s Compounders Crush Cathie Wood&#8217;s Disruptors Over The Long Haul</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Earnings Beats

Movers

Analysts Split On Roku, But One Names It 'Top Pick For 2025'

Guggenheim analyst Yatin Suneja maintains Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) with a Buy and lowers the price target from $18 to $12.

PHAT

Guggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $12

Live On CNBC, Rob Sechan Announces Bought Blackstone

Raymond James analyst Sam Darkatsh reiterates Builders FirstSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) with a Outperform and lowers the price target from $170 to $140.

BLDR

Raymond James Reiterates Outperform on Builders FirstSource, Lowers Price Target to $140

Live On CNBC, Stephanie Link Announces Bought More Eaton

Guggenheim analyst Shahriar Pourreza maintains Exelon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>) with a Buy and raises the price target from $47 to $50.

Guggenheim Maintains Buy on Exelon, Raises Price Target to $50

Health Care

Press Releases

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

Earnings

Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update

General

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Comments

Corbus Pharmaceuticals

ニュース

最新ニュース Corbus Pharmaceuticals (NASDAQ:CRBP) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル